checkAd

     855  0 Kommentare Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI - Seite 3




    Lesen Sie auch

    This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
    The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
    Source: Galapagos NV via Globenewswire

    Diskutieren Sie über die enthaltenen Werte


    GlobeNewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren
    Seite 3 von 3

    Verfasst von GlobeNewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI - Seite 3 Mechelen, Belgium; 29 April 2017, 7.30 CET -Galapagos NV (Euronext & NASDAQ: GLPG) announces presentation of pre-clinical pharmacology data with GLPG1972 at the Osteoarthritis Research Society International (OARSI) annual meeting today in Las Vegas, …